ClinicalTrials.gov record NCT07718230
Evaluation of Circadian Hormonal Balance: LC-MS/MS Measurement of Salivary and Serum Steroids in Patients With Congenital Adrenal Hyperplasia
Evaluation of Circadian Hormonal Balance: LC-MS/MS Measurement of Salivary and Serum Steroids in Patients With Congenital Adrenal Hyperplasia
AI summaryWhat this study is about, in plain languageShow ▾Hide ▴
AI-written from the registry record, not the study's own wording. May contain errors or omissions. Check the registry text on this page and the original record ↗ before acting on it.
This prospective observational study collects multiple at-home saliva samples and a routine blood (serum) sample from children with congenital adrenal hyperplasia. Steroid levels in saliva and serum will be measured by LC-MS/MS and compared, with participants followed during 1–2 routine visits over up to 12 months. The study also describes daily (nycthemeral) salivary steroid patterns and examines their relationship to hydrocortisone and fludrocortisone dosing.
What it is studying. Whether salivary steroid levels reflect paired serum levels at the 8:00 a.m. pre‑dose timepoint, how salivary steroids vary over a 24‑hour cycle, and how those patterns relate to hydrocortisone and fludrocortisone dosing.
What the researchers hope to learn. Measure the correlation between salivary and serum concentrations of multiple steroids at 8:00 a.m.; describe circadian (nycthemeral) salivary steroid profiles in CAH patients; explore relationships between salivary steroid patterns and hydrocortisone/fludrocortisone dose and schedule; provide data that could be used to model temporal steroid profiles for future monitoring tools.
What this study is about
The study's own summary, as published on ClinicalTrials.gov. Underlined terms have a short explanation.
In congenital adrenal hyperplasia (CAH), lifelong hormone replacement therapy is required to treat adrenal insufficiency and to reduce elevated androgen levels. This is essential to ensure "normal" growth and puberty. Replacement therapy includes hydrocortisone and 9α-fludrocortisone acetate (as a mineralocorticoid substitute). Defining appropriate criteria for evaluating therapeutic goals is a key component of patient follow-up. Currently, monitoring is generally limited to the quantification of serum 17-hydroxyprogesterone (17OHP), testosterone (T) and delta-4 androstenedione (D4), measured in the morning after an overnight fast and before the morning hydrocortisone dose. However, such single-point serum measurements do not take into account the circadian rhythm of these steroids. The objective of the study is to evaluate correlations between steroid levels (21-deoxycortisol, 17-hydroxyprogesterone, testosterone, delta-4 androstenedione, and cortisol) measured by LC-MS/MS in multiple at-home self-collected saliva samples and those measured in serum during routine monitoring.
Eligibility
The criteria exactly as listed on ClinicalTrials.gov. Only the study team can say whether they apply to you.
Inclusion criteria
- Patients aged 6 years or older
- Confirmed diagnosis of congenital adrenal hyperplasia treated with glucocorticoids
- Signed informed consent provided by legal guardians
- Affiliation to a national health insurance system
Exclusion criteria
- Patients younger than 6 years of age
- Lesions of the oral mucosa that could interfere with saliva sampling
- Inability to provide the patient or legal representatives with appropriate study information (e.g., poor understanding of French)
- Underage parents
- Lack of affiliation with a social security/health insurance system
Study description and what participation involves
The study's detailed description, as published on ClinicalTrials.gov.
Show the detailed description from the registry
In this project, in addition to the analysis of circulating steroids routinely performed during semi-annual follow-up, salivary steroid profiling will be performed using mass spectrometry and compared with serum measurements. The study also describe their variations over the nycthemeral cycle in a population of children with CAH. The ability to collect saliva samples at home and throughout the nycthemeral period provides significant advantages. Only five non-invasive salivary self-samples (8 a.m., 12 p.m., 4 p.m., 8 p.m., and 8 a.m.) will be requested as additional collections (1 to 2 times over 12 months). Therefore, this study does not require any additional invasive procedure beyond standard clinical follow-up. Preliminary results have demonstrated the technical feasibility of this approach. The temporal evolution of these profiles may subsequently be modelled using multivariate statistical methods to provide clinicians with innovative tools for improved therapeutic monitoring. This is a prospective, bicentric, non-interventional observational cohort study conducted in two French pediatric endocrinology centers (Hôpital Armand Trousseau and Hôpital Bicêtre). The study focuses on children with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency, treated with glucocorticoids according to current clinical practice. CAH is a rare adrenal disorder characterized by adrenal insufficiency and variable degrees of hyperandrogenism. Lifelong hormone replacement with hydrocortisone and 9α-fludrocortisone acetate is required to control androgen excess and ensure normal growth and pubertal development. Therapeutic management must strike a balance between overtreatment (risk of growth retardation, weight gain, osteoporosis, and metabolic and cardiovascular complications) and undertreatment (persistent hyperandrogenism, accelerated growth, menstrual cycle disturbances, and testicular adrenal rest tumors). Current monitoring relies mainly on single morning serum measurements of steroid profiles, especially 17-hydroxyprogesterone (17OHP), testosterone, and delta-4 androstenedione, generally sampled in the fasting state before the morning hydrocortisone dose. However, several studies have highlighted that these steroids exhibit circadian variation, and a single time-point sample may not adequately reflect overall hormone control or guide treatment optimization. Advances in liquid chromatography tandem mass spectrometry (LC-MS/MS) now allow highly sensitive and specific profiling of multiple steroids in low-concentration matrices such as saliva. This technique offers improved analytical performance compared with immunoassays, including lower detection limits, better specificity, and the possibility to quantify numerous steroids in a single run. Salivary sampling is non-invasive, feasible at home, and well suited for repeated sampling across the nycthemeral cycle. In this study, during routine follow-up visits (1-2 times per year), patients will undergo their usual serum sampling performed as part of standard care. In addition, parents and/or patients will collect five saliva samples at home over a nycthemeral cycle (8:00, 12:00, 16:00, 20:00, and the following morning at 8:00). The last salivary sample at 8:00 a.m. will be collected at the hospital on the day of the routine visit, at the same time as the serum sample and before the morning hydrocortisone dose. Thus, for each evaluation, one serum sample and five saliva samples will be available per patient. Steroid profiling (21-deoxycortisol, 17-hydroxyprogesterone, testosterone, delta-4 androstenedione and cortisol) will be performed on both serum and saliva using LC-MS/MS in the Department of Clinical Metabolomics (METOMICS) at Hôpital Saint-Antoine. The primary analysis will examine the correlation between steroid concentrations measured in saliva and serum at 8:00 a.m. using intraclass correlation coefficients and their 95% confidence intervals. Secondary analyses will characterize nycthemeral salivary steroid profiles and explore their relationship with hydrocortisone and fludrocortisone dosing regimens (dose and schedule). When repeated measurements are available for a given patient, they will be handled as repeated measures in the statistical models. The planned sample size is approximately 50 CAH patients (about 25 per center), followed for up to 12 months with 1-2 routine visits during the inclusion period. This sample size provides sufficient precision to estimate an intraclass correlation coefficient of at least 0.85 for the primary endpoint. No additional invasive procedures are required beyond standard care; the only supplementary procedures are non-invasive salivary self-samplings performed at home. Biological samples (serum and saliva) will be stored at -20°C for up to 15 months for the purposes of the study, and remaining material may be used for future research on CAH-related steroid profiles in accordance with French regulations and patient consent.
AI summaryWhat participation may involve, in plain languageShow ▾Hide ▴
AI-written from the registry record, not the study's own wording. May contain errors or omissions. Check the registry text on this page and the original record ↗ before acting on it.
Take part during 1–2 routine follow-up visits over up to 12 months with the usual blood (serum) sampling, and collect five non-invasive saliva samples at home across one 24-hour cycle (8:00, 12:00, 16:00, 20:00, and the next morning at 8:00). The final 8:00 a.m. saliva sample will be collected at the clinic at the same time as the routine serum sample and before the morning hydrocortisone dose. No additional invasive procedures are required beyond standard care. Collected serum and saliva samples will be stored (up to 15 months) and may be used for future CAH-related research according to consent and regulations.
How the study is structured. Prospective, non‑interventional observational cohort. For each routine follow-up visit, participants provide five self-collected saliva samples over 24 hours (8:00, 12:00, 16:00, 20:00, and the next morning at 8:00). The last 8:00 a.m. saliva sample is collected at the hospital at the same time as the routine serum sample and before the morning hydrocortisone dose. Samples are analyzed by LC-MS/MS; follow-up occurs during usual care visits (1–2 visits) over up to 12 months. No extra invasive procedures beyond standard care are required.
Questions you could ask
These questions are suggestions for a conversation with the study team or your own clinician, not advice.
- This is an observational study, so the study itself gives no treatment. What would taking part involve for me, and would it change my usual care?
- The registry says recruitment has not started. When is it expected to open, and can I register interest now?
- The listed sites are in France. Is any of them reachable for me, and does the study help with travel?
- Which of the eligibility criteria would need to be checked with tests before I could join?
More on congenital adrenal hyperplasia
Important dates
- Study start
- September 2026 (estimated)
- Primary completion
- September 2027 (estimated)
- Study completion
- September 2028 (estimated)
- Target enrollment
- 50 participants (estimated)
- Last updated on registry
- Jul 21, 2026
- Data verified
- Oct 10, 2026
Sponsor and research team
The lead sponsor funds and oversees the trial. A pharmaceutical or biotech company sponsor typically means the study is testing that company's drug or device; a hospital, university, or government agency usually indicates investigator-initiated or publicly funded research.
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
Central study contact
If you're interested in participating, the central contact can answer general questions about the study — including eligibility requirements and how to find a recruiting site near you. Actual eligibility is determined by the site's medical team.
- Muriel HOUANG, MD 📞 +33 1 44 73 66 31 ✉ muriel.houang@aphp.fr
- Antonin LAMAZIERE, PU-PH 📞 +33 1 40 01 14 90 ✉ antonin.lamaziere@aphp.fr
Participating sites (1)
- Service des Explorations Fonctionnelles Endocriniennes, Hôpital Armand Trousseau
Paris, 75012 · France
- Muriel HOUANG, MD · +33 1 44 73 66 31 · muriel.houang@aphp.fr
- Claire BOUVATTIER, MD · +33 1 45 21 22 75 · claire.bouvattier@aphp.fr
Terms used on this page · explanations by MedicalUpdates.ai
- follow-up
- The period after treatment or enrolment during which participants are observed or contacted, for example to record side effects or outcomes.
- glucocorticoids
- Steroid medicines, such as prednisone, that reduce inflammation. Studies often require a stable dose at entry or measure whether the study treatment allows the dose to be reduced.
- informed consent
- The process of explaining a study, including its risks and what participation involves, so that a person can decide freely whether to take part. Consent is usually documented in writing, and a participant can choose to leave the study later.
- Inclusion Criteria
- The conditions a person must meet to be considered for the study, for example a confirmed diagnosis, an age range or a test result.
- Exclusion Criteria
- The conditions that rule a person out even if they meet the inclusion criteria, for example other illnesses, certain medicines or pregnancy.
- primary endpoint
- The main result the study is designed to measure and report on. Other results, called secondary outcomes, are also collected.
The study record on this page is reproduced from ClinicalTrials.gov, a database of the U.S. National Library of Medicine, where it was submitted by the study sponsor. MedicalUpdates.ai does not own this content, is not affiliated with or endorsed by ClinicalTrials.gov, NIH, or the U.S. Government, and does not verify the record. Plain-language notes, the glossary and the questions above are added by this website; text in the boxes marked "AI summary" was written by an AI model and may contain errors. Registry records change over time. Check the original record for the current version and discuss eligibility or participation with a qualified healthcare professional.
← Back to clinical trials